Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Bioactive peptides from venoms against glioma progression
Avtorji:ID Majc, Bernarda (Avtor)
ID Novak, Metka (Avtor)
ID Lah Turnšek, Tamara (Avtor)
ID Križaj, Igor (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (2,07 MB)
MD5: 8FF101987CF0E7CD97831B943526AEBF
 
URL URL - Izvorni URL, za dostop obiščite https://doi.org/10.3389/fonc.2022.965882
 
Jezik:Angleški jezik
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:Logo NIB - Nacionalni inštitut za biologijo
Povzetek:Venoms are complex mixtures of different molecules and ions. Among them, bioactive peptides have been found to affect cancer hallmarks, such as cell proliferation, cell invasion, cell migration, and can also modulate the immune response of normal and cancer-bearing organisms. In this article, we review the mechanisms of action on these cancer cell features, focusing on bioactive peptides being developed as potential therapeutics for one of the most aggressive and deadly brain tumors, glioblastoma (GB). Novel therapeutic approaches applying bioactive peptides may contribute to multiple targeting of GB and particularly of GB stem cells. Bioactive peptides selectively target cancer cells without harming normal cells. Various molecular targets related to the effects of bioactive peptides on GB have been proposed, including ion channels, integrins, membrane phospholipids and even immunomodulatory treatment of GB. In addition to therapy, some bioactive peptides, such as disintegrins, can also be used for diagnostics or are used as labels for cytotoxic drugs to specifically target cancer cells. Given the limitations described in the last section, successful application in cancer therapy is rather low, as only 3.4% of such peptides have been included in clinical trials and have passed successfully phases I to III. Combined approaches of added bioactive peptides to standard cancer therapies need to be explored using advanced GB in vitro models such as organoids. On the other hand, new methods are also being developed to improve translation from research to practice and provide new hope for GB patients and their families.
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:29.08.2022
Leto izida:2022
Št. strani:str. 1-14
Številčenje:Vol. 12
PID:20.500.12556/DiRROS-20100 Novo okno
UDK:577
ISSN pri članku:2234-943X
DOI:10.3389/fonc.2022.965882 Novo okno
COBISS.SI-ID:119389187 Novo okno
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 28. 8. 2022; št. članka: 965882;
Datum objave v DiRROS:05.08.2024
Število ogledov:14
Število prenosov:6
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Frontiers in oncology
Skrajšan naslov:Front. oncol.
Založnik:Frontiers Editorial Office
ISSN:2234-943X
COBISS.SI-ID:1601583 Novo okno

Gradivo je financirano iz projekta

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P1-0245-2019
Naslov:Ekotoksiologija, toksikološka genomika in karcinogeneza

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P1-0207-2020
Naslov:Toksini in biomembrane

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Young Researcher grant
Številka projekta:10040137

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Nazaj